© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
Study finds estrogen alone and estrogen plus progesterone after menopause have opposite effects on breast cancer incidence.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
The Supreme Court justice recently underwent treatment for pancreatic cancer.
Cancer mortality fell by 29% between 1991 and 2017, largely driven by a decline in lung cancer deaths.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
PARP inhibitor delays disease progression when used after successful chemotherapy.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Task force recommends BRCA screening for women at increased cancer risk
Experts call for smoking cessation after cancer diagnosis
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
